Recludix Pharma

Recludix Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced program is focused on STAT6 (signal transducer and activator of transcription 6) where abnormal activation is found in inflammatory diseases, such as atopic dermatitis, asthma, rheumatoid arthritis and chronic spontaneous urticaria. The company has a strategic collaboration with Sanofi for the development and commercialization of a STAT6 inhibitor. Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional programs. Recludix was named a 2024 Fierce 15 biotech company.

Company Details

Employees
57
Phone
+1-858-258-5445
Email
in****@****dix.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Looking for a particular Recludix Pharma employee's phone or email?

Recludix Pharma Questions

News

Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewswire

Recludix Pharma to Present at the Stifel 2025 Virtual Immunology and Inflammation Forum GlobeNewswire

Recludix Pharma to Participate in Two Investor Conferences in December - Yahoo Finance

Recludix Pharma to Participate in Two Investor Conferences in December Yahoo Finance

Recludix Inks $1.3B Deal with Sanofi - San Diego Business Journal

Recludix Inks $1.3B Deal with Sanofi San Diego Business Journal

Recludix Pharma Announces Strengthening of Leadership Team, - GlobeNewswire

Recludix Pharma Announces Strengthening of Leadership Team, GlobeNewswire

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi - Yahoo Finance

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi Yahoo Finance

Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024 - Yahoo Finance

Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024 Yahoo Finance

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications - Yahoo Finance

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications Yahoo Finance

Recludix Pharma Launches with $60 Million Series A to - GlobeNewswire

Recludix Pharma Launches with $60 Million Series A to GlobeNewswire

Top Recludix Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant